On December 14, 2020 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, reported that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) (Press release, RedHill Biopharma, DEC 14, 2020, View Source [SID1234572802]). The addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Index is used to designate a set of NASDAQ-listed securities to be acquired as part of index-defined funds to be used in investment portfolios. The biotechnology index is classified according to the Industry Classification Benchmark (ICB). Companies in the biotechnology index must meet eligibility requirements, including minimum market capitalization, average daily trading volume, seasoning as a public company, and other criteria. The index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit View Source